These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 18677023)

  • 1. Low-dose physiological growth hormone in patients with HIV and abdominal fat accumulation: a randomized controlled trial.
    Lo J; You SM; Canavan B; Liebau J; Beltrani G; Koutkia P; Hemphill L; Lee H; Grinspoon S
    JAMA; 2008 Aug; 300(5):509-19. PubMed ID: 18677023
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Growth hormone-releasing hormone in HIV-infected men with lipodystrophy: a randomized controlled trial.
    Koutkia P; Canavan B; Breu J; Torriani M; Kissko J; Grinspoon S
    JAMA; 2004 Jul; 292(2):210-8. PubMed ID: 15249570
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of GH on body composition and cardiovascular risk markers in young men with abdominal obesity.
    Bredella MA; Gerweck AV; Lin E; Landa MG; Torriani M; Schoenfeld DA; Hemphill LC; Miller KK
    J Clin Endocrinol Metab; 2013 Sep; 98(9):3864-72. PubMed ID: 23824419
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Growth hormone decreases visceral fat and improves cardiovascular risk markers in women with hypopituitarism: a randomized, placebo-controlled study.
    Beauregard C; Utz AL; Schaub AE; Nachtigall L; Biller BM; Miller KK; Klibanski A
    J Clin Endocrinol Metab; 2008 Jun; 93(6):2063-71. PubMed ID: 18381581
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of recombinant human growth hormone on body composition and glucose metabolism in HIV-infected patients with fat accumulation.
    Lo JC; Mulligan K; Noor MA; Schwarz JM; Halvorsen RA; Grunfeld C; Schambelan M
    J Clin Endocrinol Metab; 2001 Aug; 86(8):3480-7. PubMed ID: 11502767
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data.
    Falutz J; Mamputu JC; Potvin D; Moyle G; Soulban G; Loughrey H; Marsolais C; Turner R; Grinspoon S
    J Clin Endocrinol Metab; 2010 Sep; 95(9):4291-304. PubMed ID: 20554713
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension.
    Falutz J; Potvin D; Mamputu JC; Assaad H; Zoltowska M; Michaud SE; Berger D; Somero M; Moyle G; Brown S; Martorell C; Turner R; Grinspoon S
    J Acquir Immune Defic Syndr; 2010 Mar; 53(3):311-22. PubMed ID: 20101189
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Growth hormone treatment of abdominally obese men reduces abdominal fat mass, improves glucose and lipoprotein metabolism, and reduces diastolic blood pressure.
    Johannsson G; Mårin P; Lönn L; Ottosson M; Stenlöf K; Björntorp P; Sjöström L; Bengtsson BA
    J Clin Endocrinol Metab; 1997 Mar; 82(3):727-34. PubMed ID: 9062473
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of insulin-like growth factor (IGF)-I/IGF-binding protein-3 treatment on glucose metabolism and fat distribution in human immunodeficiency virus-infected patients with abdominal obesity and insulin resistance.
    Rao MN; Mulligan K; Tai V; Wen MJ; Dyachenko A; Weinberg M; Li X; Lang T; Grunfeld C; Schwarz JM; Schambelan M
    J Clin Endocrinol Metab; 2010 Sep; 95(9):4361-6. PubMed ID: 20610601
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Short-term growth hormone treatment in girls with Turner syndrome decreases fat mass and insulin sensitivity: a randomized, double-blind, placebo-controlled, crossover study.
    Gravholt CH; Naeraa RW; Brixen K; Kastrup KW; Mosekilde L; Jørgensen JO; Christiansen JS
    Pediatrics; 2002 Nov; 110(5):889-96. PubMed ID: 12415026
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impaired growth hormone secretion correlates with visceral adiposity in highly active antiretroviral treated HIV-infected adolescents.
    Viganò A; Mora S; Brambilla P; Schneider L; Merlo M; Monti LD; Manzoni P
    AIDS; 2003 Jul; 17(10):1435-41. PubMed ID: 12824780
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term high-physiological-dose growth hormone reduces intra-abdominal fat in HIV-infected patients with a neutral effect on glucose metabolism.
    Hansen BR; Haugaard SB; Jensen FK; Jensen JE; Andresen L; Iversen J; Andersen O
    HIV Med; 2010 Apr; 11(4):266-75. PubMed ID: 20002779
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Growth hormone axis treatments for HIV-associated lipodystrophy: a systematic review of placebo-controlled trials.
    Sivakumar T; Mechanic O; Fehmie DA; Paul B
    HIV Med; 2011 Sep; 12(8):453-62. PubMed ID: 21265979
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discontinuing long-term GH replacement therapy--a randomized, placebo-controlled crossover trial in adult GH deficiency.
    Filipsson Nyström H; Barbosa EJ; Nilsson AG; Norrman LL; Ragnarsson O; Johannsson G
    J Clin Endocrinol Metab; 2012 Sep; 97(9):3185-95. PubMed ID: 22791760
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of growth hormone treatment on trunk fat accumulation in adult GH-deficient Japanese patients: a randomised, placebo-controlled trial.
    Chihara K; Kato Y; Takano K; Shimatsu A; Kohno H; Tanaka T; Irie M
    Curr Med Res Opin; 2006 Oct; 22(10):1973-9. PubMed ID: 17022857
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant human growth hormone and rosiglitazone for abdominal fat accumulation in HIV-infected patients with insulin resistance: a randomized, double-blind, placebo-controlled, factorial trial.
    Glesby MJ; Albu J; Chiu YL; Ham K; Engelson E; He Q; Muthukrishnan V; Ginsberg HN; Donovan D; Ernst J; Lesser M; Kotler DP
    PLoS One; 2013; 8(4):e61160. PubMed ID: 23593417
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial.
    Stanley TL; Feldpausch MN; Oh J; Branch KL; Lee H; Torriani M; Grinspoon SK
    JAMA; 2014 Jul 23-30; 312(4):380-9. PubMed ID: 25038357
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of a combination of recombinant human growth hormone with metformin on glucose metabolism and body composition in patients with metabolic syndrome.
    Herrmann BL; Berg C; Vogel E; Nowak T; Renzing-Koehler K; Mann K; Saller B
    Horm Metab Res; 2004 Jan; 36(1):54-61. PubMed ID: 14983408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of GH in women with abdominal adiposity: a 6-month randomized, double-blind, placebo-controlled trial.
    Bredella MA; Lin E; Brick DJ; Gerweck AV; Harrington LM; Torriani M; Thomas BJ; Schoenfeld DA; Breggia A; Rosen CJ; Hemphill LC; Wu Z; Rifai N; Utz AL; Miller KK
    Eur J Endocrinol; 2012 Apr; 166(4):601-11. PubMed ID: 22275471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Continuation of growth hormone (GH) replacement in GH-deficient patients during transition from childhood to adulthood: a two-year placebo-controlled study.
    Vahl N; Juul A; Jørgensen JO; Orskov H; Skakkebaek NE; Christiansen JS
    J Clin Endocrinol Metab; 2000 May; 85(5):1874-81. PubMed ID: 10843168
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.